AGI-6780 is a selective small molecule inhibitor primarily investigated for its role in targeting mutant forms of the isocitrate dehydrogenase 2 (IDH2) enzyme. It has shown potential in the study and treatment of certain cancers, particularly acute myeloid leukemia (AML), where IDH2 mutations lead to abnormal metabolic activity and accumulation of the oncometabolite 2-hydroxyglutarate (2-HG). By inhibiting the mutant IDH2 protein, AGI-6780 helps reduce 2-HG levels, promoting differentiation of immature myeloid cells and potentially halting disease progression. It is used mainly in preclinical research to understand the biological impact of IDH2 inhibition and to evaluate therapeutic strategies for IDH2-driven malignancies. Its application remains focused on oncology research, especially in developing targeted epigenetic therapies.